Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes

This study is currently recruiting participants.

Verified by Groupe Hospitalier Pitie-Salpetriere, July 2005

Sponsors and Collaborators:	Groupe Hospitalier Pitie-Salpetriere Institut National de la Santé Et de la Recherche Médicale, France
Information provided by:	Groupe Hospitalier Pitie-Salpetriere
ClinicalTrials.gov Identifier:	NCT00139321

Purpose

Gait disorders and falls are frequent in patients with parkinsonian syndromes. In patients with Parkinson's disease (PD), these signs occurred later during the course of the disease in comparison to patients with other degenerative parkinsonian disorders. The pathophysiology of these symptoms are still not fully understood. Gait initiation challenges the balance control system as the body moves from an upright stable static posture to a continuously unstable gait. The aim of this study is to analyse the gait initiation process in patients with parkinsonian disorders.

Condition	Intervention
Gait Disorders, Neurologic	Device: Force platform and electromyography

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Parkinson disease

MedlinePlus related topics: Parkinson's Disease

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Diagnostic, Non-Randomized, Open Label, Historical Control, Parallel Assignment
Official Title:	Biomechanical Parameters of Gait in Patients With Parkinson's Disease and Parkinsonian Syndromes

Further study details as provided by Groupe Hospitalier Pitie-Salpetriere:

Primary Outcome Measures:

Biomechanical gait initiation parameters

Estimated Enrollment:

110

Eligibility

Ages Eligible for Study:	18 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Patients able to walk without assistance
Patients with Parkinson's disease or other degenerative parkinsonian syndromes (progressive supranuclear palsy [PSP], multiple system atrophy [MSA], corticobasal degeneration [CBD], etc.)

Exclusion Criteria:

Other parkinsonian syndromes
Dementia
Neuroleptic treatment

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00139321

Contacts

Contact: Marie-Laure Welter, MD

33-142161950

marie-laure.welter@psl.aphp.fr

Locations

France
Centre d'Investigation Clinique-Hôpital Pitié-Salpetriere	Recruiting
Paris, France, 75013
Contact: Marie-Laure Welter, MD 33-42161950 marie-laure.welter@psl.aphp.fr
Sub-Investigator: Marie-Laure Welter, MD

Sponsors and Collaborators

Groupe Hospitalier Pitie-Salpetriere

Institut National de la Santé Et de la Recherche Médicale, France

Investigators

Study Director:

Yves Agid, MD, PhD

CIC-Pitié-Salpêtrière

More Information

Study ID Numbers:	RBM0260
Study First Received:	August 30, 2005
Last Updated:	March 15, 2006
ClinicalTrials.gov Identifier:	NCT00139321
Health Authority:	France: Ministry of Health

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:

Gait disorders
Postural instability
parkinsonian syndrome

Gait initiation
Parkinson's disease
Adults

Study placed in the following topic categories:

Signs and Symptoms
Ganglion Cysts
Movement Disorders
Parkinson Disease
Basal Ganglia Diseases
Gait Disorders, Neurologic

Neurologic Manifestations
Central Nervous System Diseases
Parkinsonian Disorders
Neurodegenerative Diseases
Brain Diseases

Additional relevant MeSH terms:

Pathologic Processes
Disease
Syndrome
Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009